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Abstract
The c-Myc oncogene (MYC) drives malignant progression, but also induces robust anabolic and 
proliferative programs leading to intrinsic stress. The mechanisms enabling adaptation to MYC-
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induced stress are not fully understood. We have uncovered an essential role for the transcription 
factor ATF4 in survival following MYC activation. MYC upregulates ATF4 by activating GCN2 
kinase through uncharged tRNAs. Subsequently, ATF4 co-occupies promoter regions of over 30 
MYC target genes, primarily those regulating amino acid and protein synthesis, including 4E-BP1, 
a negative regulator of translation. 4E-BP1 is essential to balance protein synthesis, relieving 
MYC-induced proteotoxic stress. 4E-BP1 activity is negatively regulated by mTORC1-dependent 
phosphorylation and inhibition of mTORC1 signaling rescues ATF4 deficient cells from MYC-
induced ER stress. Acute deletion of ATF4 significantly delays MYC-driven tumor progression 
and increases survival in mouse models. Our results establish ATF4 as a cellular rheostat of MYC-
activity, ensuring enhanced translation rates are compatible with survival and tumor progression.
Introduction
Cells utilize distinct stress response pathways to overcome environmental and physiological 
stresses. The Integrated Stress Response (ISR) pathway promotes cellular adaptation to 
various stresses such as viral infection, heme deprivation, hypoxia, nutrient deprivation and 
acidosis1. The ISR kinases, PKR-like ER kinase (PERK), general control non-derepressible 
2 (GCN2), double-stranded RNA-dependent protein kinase (PKR) and heme-regulated 
eIF2α kinase (HRI), sense distinct stresses and catalyze phosphorylation of the α subunit of 
the eukaryotic initiation factor eIF2 (eIF2α). Phosphorylation of eIF2α at serine 51 
attenuates general protein synthesis while enhancing the translation of select transcripts 
containing distinct regulatory sequences in their 5’ untranslated region2, 3, most notably that 
of the activating transcription factor 4 (ATF4). Once translated, ATF4 drives the 
transcription of genes involved in antioxidant response, autophagy, amino acid biosynthesis 
and transport4, 5.
The ability of cancer cells to adapt to cell-extrinsic and intrinsic stresses is critical for 
maintaining viability and growth. We and others previously showed that the ISR is essential 
in adaptation to extrinsic stresses present in the tumor microenvironment such as hypoxia 
and nutrient deprivation6–9. Cancer cells also experience intrinsic stress due to activation of 
oncogenes that increase bioenergetic processes10–12. In this context, amplification of the 
MYC oncogene, a frequent event in multiple human malignancies13 causes intrinsic stress 
due to enhanced protein synthesis and rewired metabolic pathways to meet the demands of 
rapid cell growth and proliferation14, 15. MYC upregulates protein synthesis by 
transactivating components of the translational machinery including initiation factors, 
ribosomes and tRNAs15 and targeting the translation machinery has proven to be effective in 
MYC-driven cancers16, 17. However, protein synthesis rates need to be controlled to a 
critical level to sustain survival of cancer cells during tumor development. For example, 
increased protein synthesis has to be accompanied by a concomitant increase in the folding 
capacity and size of the Endoplasmic Reticulum (ER) to avoid proteotoxicity18.
We previously demonstrated that MYC-induced increase in translation rates activates the 
PERK arm of ISR, which is required for supporting MYC induced transformation and 
survival11, primarily by activating cytoprotective autophagy and attenuating Ca2+ release 
from the ER11. Although ATF4 has been implicated in supporting survival of cancer cells 
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experiencing a deficit of oxygen and nutrients, its role in oncogene-induced stress has not 
been well characterized.
Here, we show that optimal ATF4 expression upon MYC dysregulation requires both the 
PERK and GCN2 kinases, the latter being activated by excess uncharged amino acids 
produced by increased MYC activity. Induced ATF4, cooperatively with MYC, co-regulates 
a number of gene products including 4E-BP1 to fine-tune mRNA translation induced by 
MYC. Importantly, ablation of ATF4 results in increased ER stress and cytotoxicity which is 
attenuated by mTORC1 inhibition or expression of a dominant-negative 4E-BP1. Our results 
demonstrate the critical role of ISR signaling-induced ATF4 in supporting cell adaptation 
and survival during MYC-dependent tumor growth and progression.
Results
ATF4 is induced by MYC and promotes survival.
We previously reported that activation of MYC leads to phosphorylation of PERK and 
eIF2α11. To test whether MYC activation also induces ATF4, we analyzed ATF4 expression 
following MYC induction in DLD-1, human colon adenocarcinoma cells and mouse 
embryonic fibroblasts (MEFs) stably expressing a tamoxifen-inducible MYC chimera, 
MycER. Treatment with 4-hydroxy-tamoxifen (4-OHT) led to accumulation of nuclear 
MYC and expression of ATF4 in both cell lines (Fig. 1a, Supplementary Fig. 1a). Similarly, 
in the human Burkitt’s lymphoma cell line P493–6, in which expression of MYC is turned 
off by administration of tetracycline, suppression of MYC resulted in a concomitant 
decrease of ATF4. Upon restoration of MYC levels, ATF4 protein levels also recovered (Fig. 
1b). These data indicate that elevated MYC induces ATF4 expression.
Notably, ablation of ATF4 in MEFs significantly enhanced MYC-induced cell death, 
highlighted by increased levels of the apoptosis markers including cleaved Poly-ADP ribose 
polymerase, cl-PARP, cleaved caspase 3 (Fig. 1c), and by reduced clonogenic survival (Fig. 
1d). Similarly, knockdown of ATF4 in DLD-1 cells also markedly enhanced apoptosis 
following MYC activation (Fig. 1e). Collectively, these results highlight a significant role for 
ATF4 in promoting survival of transformed cells upon MYC activation.
PERK and GCN2 are required for optimal phosphorylation of eIF2α following MYC 
induction.
Activation of MYC enhances protein synthesis resulting in ER stress11, 19. Although PERK 
is primarily responsible for phosphorylating eIF2α during MYC activation, residual 
phosphorylation of eIF2α in PERK knockout cells prompted us to ask whether other ISR 
kinases phosphorylate eIF2α in the absence of PERK11. We focused on GCN2, a kinase we 
and others have shown to be activated in multiple solid tumors7, 20. Interestingly, we noted 
robust phosphorylation of GCN2 following MYC activation (Figs. 2a and 2b). Consistent 
with our previous report11, phosphorylation of eIF2α was reduced, but still present upon 
PERK knockdown (Fig. 2b). Notably, eIF2α phosphorylation was markedly reduced in the 
absence of both kinases, indicating functional compensation between these kinases upon 
MYC activation (Fig. 2b).
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Consistent with ATF4 loss, knockdown of both PERK and GCN2 enhanced apoptosis 
following MYC activation (Fig. 2b). Decreased expression of either PERK or GCN2 also 
reduced ATF4 protein levels (Fig. 2b), and this effect was more prominent in GCN2 
knockdown cells. Similarly, transformed GCN2 deficient MEFs failed to induce ATF4 
following MYC activation (Fig. 2c). Interestingly, we observed higher activation of PERK in 
the absence of ATF4 suggesting increased ER stress in these cells (Fig. 2c). Because GCN2 
deficient cells still displayed residual p-eIF2α, yet ATF4 protein was absent compared to 
GCN2 proficient cells, we hypothesized that GCN2 may be also regulating ATF4 at the 
transcriptional level. Indeed, induction of MYC resulted in a significant upregulation of 
ATF4 mRNA only in GCN2 proficient cells, though another well-characterized MYC target 
gene, ornithine decarboxylase (ODC1) was activated independently of GCN2 
(Supplementary Fig. 1b). These results indicate that GCN2 is required not only for efficient 
ATF4 protein expression but also contributes to its mRNA transcription in response to MYC 
activation.
MYC increases the ratio of uncharged tRNAs leading to activation of GCN2.
Amino acid deficiency leads to accumulation of uncharged tRNAs which in turn bind to 
GCN2 resulting in its autophosphorylation and activation3. Activated GCN2 subsequently 
phosphorylates eIF2α, resulting in transient inhibition of general protein synthesis during 
amino acid deprivation conditions21. Therefore, we sought out to determine the mechanism 
of robust phosphorylation of GCN2 following MYC activation in cells grown in complete 
media (Fig. 2a). MYC has been shown to robustly enhance transcription of tRNAs in RNA 
POL III-dependent manner22 suggesting that newly synthesized, uncharged tRNAs might 
activate GCN2. To test this, we pretreated cells with a specific RNA polymerase III inhibitor 
ML6021823 to suppress tRNA synthesis prior to MYC activation. ML60218 markedly 
reduced GCN2 phosphorylation, indicating that RNA POL III mediated transcription of 
tRNAs is required for MYC activation of GCN2 (Fig. 2d).
RNA polymerase III regulates the transcription of other small structured RNAs including 
tRNAs22. To directly analyze the levels of aminoacyl-tRNAs following MYC activation, we 
used tRNA-tailored microarrays that distinguish charged vs uncharged tRNAs24. We found a 
striking and time-dependent increase in the levels of multiple uncharged tRNAs following 
MYC activation (Fig. 2e). There was also a pronounced increase in the overall abundance of 
tRNAs (Supplementary Fig. 1c); principal component analysis (PCA) revealed these 
changes were strongly associated with tRNAs charged with hydrophobic amino acids and in 
particular, with branched amino acids (Supplementary Fig. 1d). As expected, leucine 
deprivation led to increased uncharging of all leu tRNA isoacceptors, demonstrating the 
specificity of the assay (Fig. 2e). Furthermore, inhibition of RNA polymerase III markedly 
increased the fraction of charged tRNAs (Supplementary Fig. 1e) by reducing the total 
amount of all tRNAs (Supplementary Fig. 1f). These data indicate that MYC-induced RNA 
polymerase III dependent transcription of tRNAs leads to transient accumulation of 
uncharged tRNAs, thereby activating GCN2.
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ATF4 and MYC have common (overlapping) DNA binding sites.
Since ATF4 is critical for survival following MYC activation (Fig. 1c–e), we performed 
chromatin immunoprecipitation (ChIP)-sequencing in DLD-1:MycER cells with or without 
MYC activation to map genes bound by ATF4 on a genome-wide scale. We identified 330 
unique ATF4 binding sites that had ATF4 ChIP-seq signal significantly enriched (FDR<5%, 
at least 4-fold) over IgG control (Fig. 3a). Approximately 50% of the binding sites (165 out 
of 330) were significantly increased following MYC activation for 8 hrs (Fig. 3a). De-novo 
motif search revealed that ~90% of identified ATF4 binding sites contained a previously 
established mouse ATF4 binding motif25 (GSE35681) (Fig. 3b). From the 165 ATF4 binding 
sites, we identified 79 genes (with Entrez ID) where ATF4 occupied within 5kb from at least 
one gene transcription start site (TSS). Of this subset, 16 genes are previously well-
characterized ATF4 targets4, 25 (Supplementary Fig. 2a). Analysis of the 79 gene list for 
functional and pathway enrichment showed significant overrepresentation of 11 functional 
categories and 10 pathways (Supplementary Fig. 2b). As expected, one of the pathways was 
the UPR confirming the well-characterized role of ATF4 in this pathway. Other key 
functional categories were amino acid transport and biosynthesis and tRNA synthetases 
underscoring the important role of ATF4 in protein synthesis (Supplementary Fig. 2b). We 
then analyzed the gene list for enrichment of known transcriptional regulators to identify 
potential ATF4 co-regulators (Fig. 3c). As expected, ATF4 itself was the top significant hit 
with 16 known targets and a Z-score indicating positive regulation (Z=3.88, based on the 
majority of targets being upregulated by ATF4). Intriguingly, the only other significant 
transcriptional co-regulator was MYC with a Z score of at least 1.5, higher than additional 
factors such as p53, SP1 and Pax3 that also had significant enrichment of targets.
We then performed ChIP-seq for MYC to map its global binding following stimulation with 
4-OHT in the same cells. This experiment identified 3263 peaks at 8hr of MYC induction 
that were within 5kb from a gene TSS, 33 of which overlapped with ATF4 binding sites 
(28% of all ATF4 peaks), a significant overlap (2.1 more than expected by chance, p=2×10−5 
by hypergeometric test) suggesting similar mechanism regulating a significant subset of 
genes by both MYC and ATF4 (Fig. 3d). Moreover, the promoters of genes with functions in 
amino acid transport (SLC7A11, SLC38A1, SLC43A1) and tRNA charging (IARS, MARS, 
NARS) were occupied by both ATF4 and MYC (Fig. 3e). We validated the ChIP-seq results 
by ChIP-qPCR (Supplementary Fig. 2c). A ChIP-seq profile at a representative MYC and 
ATF4 target loci, TBC1D16, (Fig. 3e) shows overlapping binding of both MYC and ATF4 
(Fig. 3f). The ChIP-seq result suggests that MYC and ATF4 share common target genes, 
most of which are involved in amino acid transport and tRNA charging process.
ATF4 suppresses mTORC1 dependent signaling to prevent proteotoxicity following MYC 
activation.
We then sought to determine the mechanism by which ATF4 exerts its pro-survival effects 
following MYC dysregulation. Given the known role of ATF4 in amino acid metabolism, 
antioxidant response, and fatty acid synthesis, we attempted to rescue ATF4 deficient cells 
by supplying metabolites in trans in culture media under conditions of MYC 
activation4, 5, 26. ATF4 deficient MEFs require the presence of non-essential amino acids and 
antioxidants to grow4. Supplementaiton with additional antioxidants or long chain fatty acids 
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did not rescue ATF4 deficient cells (Supplementary Fig. 3a, 3b). Notably, supplementation 
with alpha-ketoglutarate (αKG), an intermediary of the TCA cycle, delayed apoptosis 
during earlier (16hr) but not later (24h) time points of MYC activation in ATF4 deficient 
MEFs (Supplementary Fig. 3a, 3c). These results suggest that MYC activation imposes 
metabolic stress which can be partially relieved by αKG. However, additional ATF4-
dependent processes must be activated to maintain long-term cell viability.
One of the targets identified by ChIP-seq to be bound by both MYC and ATF4 was the 
negative regulator of the major cap-binding protein eIF4E, EIF4EBP1 (4E-BP1), a 
downstream substrate of mammalian target of rapamycin complex 1 (mTORC1) (Fig 3e, 
Fig. 4a). mTORC1 integrates oncogenic stimuli into protein synthesis and cell growth 
signaling27 by promoting phosphorylation of p70S6K and 4E-BP128. Hyperphosphorylation 
of 4E-BP1 by mTORC1 leads to its dissociation from eIF4E, enhancing cap-dependent 
protein translation downstream of eIF4E29. We confirmed that both ATF4 and MYC bind to 
the intron of 4E-BP1 (Fig. 4a). Moreover, 4E-BP1 mRNA was reduced in the absence of 
ATF4 in both DLD-1 and MEFs (Supplementary Fig. 4a, 4b). We also observed that MYC 
activation enhanced levels of both phosphorylated and total 4E-BP1 (Fig. 4b, Fig. 4d, Fig. 
4e, and Supplementary Fig. 4c), yet there was a marked reduction in 4E-BP1 accumulation 
in the absence of ATF4 (Fig. 4b, Fig. 4d, Fig. 4e, and Supplementary Fig. 4c) indicating that 
ATF4 is required for MYC-induced 4E-BP1. Intriguingly, loss of ATF4 resulted in 
upregulation of PERK phosphorylation (Fig. 4c), indicating ER stress activation. These 
results strongly suggest that 4E-BP1, downstream of the MYC-ATF4 axis, acts as a rheostat 
to set a protein synthesis level compatible with MYC oncogenic activity. ATF4 deficient 
cells also exhibited sustained phosphorylation of p70S6K (Fig. 4b and Supplementary Fig. 
4c). We next examined whether mTORC1 suppression in ATF4 deficient cells impacted cell 
death during MYC activation. Indeed, inhibition of mTORC1 by rapamycin treatment led to 
a marked decrease in MYC-dependent apoptosis and enhanced clonogenic survival in ATF4 
deficient cells (Fig. 4d, Supplementary Fig. 4c and Supplementary Fig. 4d).
To further probe the link between ATF4 and mTORC1 effectors, we knocked down p70S6K 
and eIF4E, two major translational regulators downstream of mTORC1 signaling in the 
absence of ATF4. Consistent with the rapamycin treatment results, knockdown of p70S6K 
reduced cell death due to ATF4 deficiency when MYC was activated (Fig. 4e). Interestingly, 
combined knockdown of S6K and ATF4 resulted in feedback upregulation of 4E-BP1 and 
p-4EBP levels (Fig. 4e). Additionally, knockdown of both p70S6K and eIF4E further 
reduced cell death in the absence of ATF4 (Fig. 4e). This suggests that ATF4 is required for 
defenses against proteotoxicity in the context of hyperactive MYC-mTORC1 signaling 
funneled through p70S6K and eIF4E.
In support of this notion, inhibiting protein synthesis with low doses of cycloheximide led to 
a similar reduction in cell death in ATF4 deficient cells (Fig. 4f). However, we did not 
observe a general increase in rate of translation by 35S-Methionine and Cysteine labeling in 
the absence of ATF4, suggesting that synthesis of specific proteins rather than global 
translation is deregulated in ATF4 deficient cells and contributes to ER proteotoxicity 
(Supplementary Fig. 4e). Furthermore, treatment with a chemical chaperone 4-Phenylbutyric 
acid (4-PBA) which can protect against proteotoxicity under other stress contexts30, also 
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promoted survival of ATF4 deficient cells following MYC activation (Supplementary Fig. 
4f). Since 4E-BP1 levels were reduced in the absence of ATF4, we overexpressed a mutant 
version of 4E-BP1 that cannot be phosphorylated and inactivated by mTORC131. Expression 
of the 4E-BP1 mutant led to decreased apoptosis in ATF4 knockdown cells (Fig. 4g) which 
was further reduced when combined with knockdown of S6K (Supplementary Fig. 4g). 
Collectively, these data indicate that inhibiting both branches of mTORC1 signaling in 
ATF4-deficient cells reduces the demand of specific protein synthesis and promotes 
adaptation to hyperactive MYC-induced gene expression, mitigating proteotoxicity.
Inhibition of both PERK and GCN2 promotes survival of MYC driven lymphoma bearing 
mice.
To test the importance of the GCN2-eIF2α-ATF4 pathway in vivo, we used a well 
characterized mouse model of MYC-driven lymphoma, Eμ-myc32 which harbors MYC 
coupled to the IgH enhancer and succumb to aggressive B-cell lymphoma between 6–15 
weeks of age32. Gcn2−/− mice are viable and fertile, unlike Atf4−/− mice which show several 
pathological abnormalities in utero or shortly after birth33–35. We generated Eμ-myc/+; 
GCN2+/+, Eμ-myc/+; GCN2+/− and Eμ-myc/+; GCN2−/− mice (Supplementary Fig. 5a). 
Surprisingly, loss of GCN2 did not affect tumor initiation or progression or impact overall 
mouse survival (Supplementary Fig. 5b). Assessment of ISR signaling in B cells from each 
genotype revealed robust PERK and eIF2α phosphorylation and ATF4 upregulation in B cell 
lymphoma compared to normal B cells from littermate controls, suggesting that PERK is 
likely compensating for loss of GCN2 (Supplementary Fig. 5c).
To test this notion, we transplanted either Eμ-myc/+; GCN2+/+ or Eμ-myc/+; GCN2−/− 
lymphomas (Supplementary Fig. 5d) into C57BL/6J mice and targeted PERK by using a 
potent and specific PERK inhibitor, LY-436. LY-4 treatment was well tolerated and did not 
affect body weight or pancreas weight37 but significantly reduced phosphorylation of PERK 
(Supplementary Figs. 5e, 5f and 5h). Inhibition of PERK in mice bearing Eμ-myc/+; 
GCN2−/− lymphomas, but not Eμ-myc/+; GCN2+/+ lymphomas, increased overall survival 
(Supplementary Fig. 5g). Consistent with our in vitro data, inhibition of both PERK and 
GCN2 significantly reduced phosphorylation of eIF2α in the lymphoma cells 
(Supplementary Figs. 5h and 5i). Unexpectedly, inhibition of PERK and GCN2 did not 
reduce ATF4 protein levels, suggesting an eIF2α-independent regulation of ATF4 in the Eμ-
myc lymphoma model (Supplementary Fig. 5h). One possible explanation for the modest 
increase in survival of these mice is the decreased phosphorylation of eIF2α which can 
exacerbate ER stress in tumor cells due to unregulated protein translation38. These results 
underscore a strict selective pressure for maintenance of robust ATF4 levels in MYC-driven 
tumors.
Acute ablation of ATF4 in lymphoma cells significantly enhances tumor-free survival and 
overall survival.
The results with the Eμ-myc/+; GCN2−/− mice indicated that maintenance of ATF4 may be 
important for tumor progression. Therefore, we generated conditional knockout ATF4fl/fl 
mice and crossed the Eμ-myc/+ with Rosa26-CreERT2/+ mice39, which express a tamoxifen 
inducible Cre recombinase enzyme. Eμ-myc/+; Rosa26-CreERT2/+ were crossed with 
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ATF4fl/fl mice to generate Eμ-myc/+; ATF4wt/wt; Rosa26-CreERT2/+ and Eμ-myc/+; 
ATF4fl/fl; Rosa26-CreERT2/+ genotypes (Supplementary Fig. 6a and Supplementary Fig. 
6b). Following lymphoma onset, lymphoma cells were purified and allografted by 
intravenous injection into C57BL/6 syngeneic mice. The recipient mice were treated either 
with vehicle or tamoxifen to excise ATF4 specifically in the lymphoma cells (Fig 5b). 
Remarkably, excision of ATF4 significantly extended lymphoma-free and overall survival 
(Fig. 5b, 5c). This effect was not due to tamoxifen treatment because mice with Eμ-myc/+; 
ATF4wt/wt; Rosa26-CreERT2/+ lymphomas displayed no significant difference in lymphoma-
free or overall survival (Supplementary Fig. 6c and Fig. 5c).
To further assess the requirement for ATF4 in lymphoma progression, we treated a separate 
cohort of mice as above once lymphoma developed. Treatment with tamoxifen resulted in 
efficient ablation of ATF4 mRNA (Supplementary Fig. 6d) and protein as well as reduction 
in ATF3, an ATF4 target gene (Fig. 5d) and resulted in reduced lymph node weight (Fig. 5e). 
Consistent with our in vitro data (Fig. 4b and Supplementary Fig. 4c), 4E-BP1 levels were 
significantly reduced in lymphoma cells following ATF4 ablation (Fig. 5f). However, ATF4 
expression returned to levels comparable to those of vehicle-treated groups by the endpoint 
of the experiment, suggesting that lymphoma cells that escaped ATF4 excision eventually 
formed lymphomas (Supplementary Fig. 6e).
Similar to the lymphoma model, knockdown of ATF4 in DLD-1:MycER cells expressing a 
doxycycline inducible short-hairpin RNA against ATF4, significantly delayed tumor growth 
(Fig. 5g). Collectively, the in vivo data support our hypothesis that ATF4 is critical for tumor 
growth driven by hyperactive MYC and indicate that targeting ATF4 in the context of 
activated MYC elicits potent anti-tumor effects.
We next assessed the levels of ISR signaling in B cells isolated from WT, pre-lymphoma and 
lymphoma bearing Eμ-myc mice. We noted higher expression of ATF4 in lymphoma 
samples compared to WT and pre-lymphoma samples (Fig. 6a). Interestingly, levels of p-
eIF2α, p-4E-BP1, 4E-BP1 and p-p70S6K were higher in both pre-lymphoma and lymphoma 
samples (Fig. 6a). Human Burkitt’s lymphoma cell lines also displayed robust increases in 
ISR signaling and 4E-BP1 levels (Fig. 6b). Similar results were seen in human breast and 
colon cancer cell lines compared to a human immortalized breast epithelial cell line and 
normal human colonocytes respectively (Fig. 6c and Fig. 6d).
To investigate the relevance of our findings in human malignancy, we analyzed the 
expression of 4E-BP1 and tested its correlation with ATF4 activity in different cohorts of 
cancer patients by mining the TCGA database. Since ATF4 is primarily regulated at the 
translational level, we used a group of 10 well-characterized ATF4 targets (including ASNS, 
MTHFD2, CHOP) as a surrogate for ATF4 activation4, 25. We found that 4E-BP1 levels 
displayed a significant positive correlation with ATF4 target genes in DLBCL, colorectal 
cancer, breast cancer and sarcoma (Fig. 6e). Notably, high expression of 4E-BP1 also 
correlated with poor prognosis in DLBCL patients (Fig. 6f). These data further support the 
notion that ATF4-dependent modulation of MYC-driven translational alterations may play a 
role in progression of MYC-driven lymphomas.
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Discussion
MYC activation is invariably linked with enhanced protein synthesis critical for enhanced 
proliferation and manifestation of MYC’s tumorigenic properties40. However, increased 
translation places heightened demands on the ER, the site for glycosylation and folding of 
client proteins41. While PERK-mediated phosphorylation of eIF2α can provide initial relief 
from increased translation rates11, this mechanism may be insufficient for long-term survival 
due to a negative feedback loop that promotes dephosphorylation of eIF2α42. This work 
demonstrates that ATF4 is critical for MYC-dependent tumor progression by not only 
supporting protein synthesis via expression of amino acid transporters and tRNA synthetases 
but also by preventing “runaway” mRNA translation and subsequent proteotoxicity via 
prolonged upregulation of 4E-BP1 levels (Fig. 6g).
Since ablating ATF4 expression did not increase global translation levels following MYC 
dysregulation, it is likely that ATF4 negatively regulates the expression of a specific set of 
proteins that traffic through the ER. This notion is supported by the following findings: (a) 
Absence of ATF4 in a background of MYC activation results in robust PERK 
phosphorylation, a sensitive sensor of ER stress; (b) Rapamycin or CHX treatment rescues 
MYC-driven, ATF4-deficient cells from apoptosis; and (c) A chemical ER chaperone 
rescues ATF4 deficient cells. In the future, it will be important to identify the specific 
mRNAs that are selectively translated under the control of the ATF4–4E-BP1 axis.
4E-BP1 has been shown to inhibit cap dependent translation and to promote survival under 
conditions of nutrient and oxidative stress43. Interestingly, higher expression of 4E-BP1 has 
been noted in multiple cancers44–46 and its high expression is associated with poor 
prognosis45–47. While ATF4 has been shown to regulate 4E-BP1 in the context of extrinsic 
physiologic stresses48, 49, its role in regulating 4E-BP1 in the context of MYC-deregulated 
tumor progression had not been previously reported. Higher expression of 4E-BP1 seems 
paradoxical, as a hyperactive form of 4E-BP1 blocks MYC-induced tumorigenesis50. 
Indeed, our findings provide a novel context as to why 4E-BP1 expression is upregulated in 
tumors: rather than downregulating its levels, tumors maintain high levels of 4E-BP1 whose 
activity can be readily modulated by rapid phosphorylation-dephosphorylation depending on 
favorable/unfavorable growth and proliferation conditions.
Our study also highlights the importance of using combined inhibition of both PERK and 
GCN2 in MYC driven cancers to avoid compensation of ISR kinases in regulating p-eIF2α 
levels. Indeed, pharmacologic targeting of eIF2α phosphorylation in patient-derived prostate 
xenograft models is effective in initiating cytotoxic response inhibiting tumor growth38. 
However, in the lymphoma model tested here, ATF4 levels remained high despite the near 
complete inhibition of upstream canonical pathways (potentially via translational regulation 
by mTOR)51 and acute ATF4 ablation significantly decreased tumor growth and prolonged 
survival. This strongly implies that for certain malignancies, it might be essential to directly 
inhibit ATF4 activity for optimal antitumor outcome. Taken together, the ISR transcription 
factor ATF4 is necessary for supporting and censoring protein translation thus promoting 
progression of MYC driven tumorigenesis.
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Methods
Cell culture and reagents.
Human colon adenocarcinoma cell line DLD-1, Burkitt’s lymphoma cell lines Raji and 
Ramos as well as human breast cancer cell lines, MCF10A, MCF-7 and MDA-MB-231 were 
purchased from American Type Culture Collection (ATCC). DLD-1 cells were maintained in 
DMEM (Invitrogen #21063–029) supplemented with 10% FBS (Sigma) and 1% penicillin-
streptomycin (Invitrogen). P493–6 cells were provided by Dirk Eick, German Res. center for 
Environmental Health, Helmholtz center, Munich. P493–6, Raji and Ramos were maintained 
in RPMI-1640 supplemented with 10% FBS and 1% Penicillin-Streptomycin. MYC 
expression was turned off in P4936 cells by adding 0.1μg/ml Tetracycline. Wild-type and 
Gcn2-knockout, Sv40 immortalized, mouse embryonic fibroblasts (MEFs) were purchased 
from ATCC. Atf4-knockout Sv40 immortalized MEFs were a gift from David Ron 
(Cambridge Institute for Medical Research (CIMR). Wild-type, Atf4-knockout, Gcn2-
knockout, Sv40 immortalized, MEFs were maintained in DMEM supplemented with 10% 
FBS, 1% Penicillin-Streptomycin, 1x non-essential amino acids (Invitrogen, #11140050) 
and 55 μM β-mercaptoethanol (Millipore, #ES-007-E). DLD-1 cells and MEFs were 
infected with retroviruses expressing MycER. MycER was induced with 250nM or 500nM 
of 4-hydroxytamoxifen (4-OHT, Sigma-H7904) in MEFs or DLD-1 cells, respectively. All 
cells were determined to be free of mycoplasma and cultured in 5% CO2 at 37°C. Normal 
human colonocytes were purchased from Cell Applications Inc (732Cn-10a). Normal 
primary B cells were purchased from the Human Immunology Core at University of 
Pennsylvania. RNA POL III inhibitor ML60218 (577784-91-9), cyclohexamide (C7698) and 
rapamycin (R8781) were purchased from Sigma. 4PBA (130380250) was purchased from 
Fisher Scientific. siRNAs against ATF4 (L-005125–00), PERK (L-004883–00), GCN2 
(L-005314–00), p70S6K (L-003616–00), eIF4E (L-003884–00) and non-targeting siRNA 
(D-001810–10) control were purchased from Dharmacon. LY-4 was provided by Eli Lilly.
Plasmids and retroviruses.
MycER plasmid was provided by Dr. Andrei Thomas-Tikhonenko (The Children’s Hospital 
of Philadelphia). Retrovirus construct and packaging plasmids, pEco-clontech (for mouse 
cells), pAmpho-clontech (for human cells) and gag pol were co-transfected into 293T cells 
by lipofectamine 2000 (Invitrogen), according to manufacturer’s instructions. Retroviral 
supernatant was collected 48–72hours post transfection and supplied with 8μg/ml polybrene 
(28728-55-4 Sigma) to infect target cells. Lentiviral TRIPZ inducible shRNA against ATF4 
plasmid was purchased from Dharmacon (V3THS_132755). Lentivirus was made in 293T 
cells by co-transfecting lentiviral vector and packaging plasmids. Lentiviral supernatant was 
collected 48–72 hours post transfection and used to infect target cells. The dominant 
negative mutant of 4EBP1 (DN-4EBP1) cDNA has been previously described52. The 
DN-4EBP1 cDNA was subcloned into pMSCV-hygro to generate a constitutive mammalian 
expression vector with N-terminal flag tag (4E-BP1 Mutant) used in this study. Retrovirus 
was made as described earlier to transfect DLD-1, MycER cells. Transduced cells were 
selected with 400μg/ml Hygromycin to make stable cell lines.
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Immunoblotting and antibodies.
Cells were harvested in ice cold PBS and nuclear and cytoplasmic fractions were isolated by 
BioVision Nuclear Cytoplasm fractionation kit according to manufacturer’s instructions 
(BioVision K266). RIPA buffer supplied with protease inhibitors (Roche 11836153001) and 
phosphatase inhibitors (p5726, p0044, Sigma) was used for whole lysate isolation. Protein 
concentrations were determined by DC protein assay (BioRad). Equal protein was loaded 
and resolved on to sodium dodecyl sulfate polyacrylamide gels and transferred to 
polyvinylidene fluoride membranes. All antibodies were incubated overnight at 40C 
overnight in 5% TBS (20mM Tris-Base and 150mM NaCl), 0.1% Tween-20. Membranes 
were washed and incubated with secondary antibodies for 1 hour. Membranes were exposed 
to autoradiography films after washing with TBS, 0.1% tween. The following antibodies 
were used for detecting proteins: ATF4 (cat# sc-200x, c-20), MYC (cat# sc-764, N-262), 
ATF3 (cat# sc-188, C-19) were purchased from Santa Cruz. Rabbit β-tubulin (2146), mouse 
cl-PARP (mouse specific, #9548, 7C9), rabbit cl-PARP (human specific, cat#9541), rabbit 
cl-caspase3 (cat# 9661), rabbit GCN2 (cat# 3302), rabbit PERK (cat# 3192, C33E10), rabbit 
p-PERK T980 (cat# 3179,16F8), rabbit p-4EBP1 T37/46 (cat# 2855, 236B4), rabbit 4EBP1 
(cat#9452), rabbit eIF4e (cat#9742), rabbit p-p70S6K T389 (cat# 9205), rabbit p70S6K 
(cat#2708, 49D7), rabbit p-eIF2α S51 (cat# 3597, 119A11) and rabbit eIF2α (cat# 9722) 
were all purchased from Cell Signaling Technology. Rabbit p-PERK T982 was provided by 
Eli Lilly. Rabbit p-GCN2 T899 (cat# ab 75836) was purchased from Abcam. Mouse β-actin 
(cat#A5441, AC-15) was purchased from Sigma. Mouse RNA POL II (cat# 39097) was 
purchased from Active Motif. Horseradish peroxidase- conjugated secondary antibodies, 
goat anti mouse (cat#31430) and goat anti rabbit (cat#31460) were purchased from Thermo 
Scientific.
Clonogenic survival assay.
Cells were grown in complete media in 60mm dishes or in 6-well plates. The following day, 
cells were treated with 4-OHT. Media was changed after 24 hours. Colonies that formed 
after a week were fixed with a solution of 10% methanol and 10% acetic acid and then 
stained with 0.4% crystal violet in 20% ethanol.
35S Methionine and Cysteine labeling.
Cells were plated in 6 well dish. The following day, cells were treated with 4-OHT for 
indicated times and cells were labeled with 50μCi Met/Cys Express Mix (PerkinElmer, 
NEG772014MC) for 1hr in Methionine and cysteine free DMEM (21013024, Invitrogen). 
Cells were washed with ice cold PBS and cell lysates were harvested for protein. Equal 
protein was loaded and resolved on to sodium dodecyl sulfate polyacrylamide gels and 
transferred on to polyvinylidene fluoride membranes. Membranes were exposed to 
autoradiography films. 35S incorporation was quantified by Image J software. β-actin was 
used as a loading control.
Magnetic isolation of mouse B cells.
Spleens and lymph nodes were excised from euthanized mice and immediately passed 
through 70μm cell strainer. Normal splenic B cells as well as B cells in lymphoma were 
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isolated by using mouse B cell isolation kit (130-090-862, Miltenyi Biotec) according to 
manufacturer’s instructions.
Quantitative Real Time PCR.
RNA was harvested for qPCR analysis by using Qiagen RNeasy Mini Kit (74104) according 
to manufacturer’s instructions. RNA was reverse transcribed by using AMV reverse 
transcriptase (Promega, M5108) in the presence of RNase inhibitor (Promega, N2111). 
qPCR was performed with Power SYBR green PCR master mix (Applied Biosystems, 
4367659). QuantStudio 6 Flex Real-Time PCR System (Applied Biosystems) was used for 
data analysis. Primers used for qPCR are listed in Supplementary Table 1.
Apoptosis analysis.
Apoptosis was detected using the annexin V apoptosis detection kit (Invitrogen, # A23204) 
according to the manufacturer’s instructions. Briefly, Cells were collected and 1×105 cells 
were resuspended in 100μl annexin-binding buffer. 5μl of the annexin V conjugate was 
added to each 100μl of cell suspension and incubated at room temperature for 15 minutes. 
An additional 400μl of annexin-binding buffer was added to cells. Cells were immediately 
analyzed on BD FACS Canto flow cytometer.
tRNA charging microarray.
About 8 million DLD-1, MycER cells were treated with 500nM 4-OHT for 2h, 4h, 8h or 
EtOH was used as vehicle. To determine the fraction of charged tRNAs, total RNA was 
isolated in mild acidic conditions using acidic phenol (pH 4.5) whose low pH preserves the 
aminoacyl-moiety. Each sample was split into two aliquots and one was oxidized with 
periodate which oxidizes the free non-aminoacyl groups leaving the changed tRNAs intact. 
Following subsequent deacylation the amino acid-protected tRNAs hybridize to Cy3-labeled 
RNA/DNA stem-loop oligonucleotide. The second aliquot was deacylated in 100 mM Tris 
(pH 9.0) at 37°C for 45 min and hybridized to Atto647-labeled RNA/DNA stem-loop 
oligonucleotide and designated as total tRNA. Both aliquots were loaded on tRNA 
microarrays with tRNA probes covering the full-length sequence of cytoplasmic tRNA 
species as described previously53. For tRNA abundance, total RNA was isolated with 
TriReagent (Sigma Aldrich) which alkaline pH simultaneously deacylates all tRNAs. The 
tRNAs were subsequently labeled with by ligating Cy3-labeled RNA/DNA stem-loop 
oligonucleotide. The tRNAs isolated from the vehicle treated sample were labeled with 
Att647-labeled RNA/DNA stem-loop oligonucleotide, loaded on all arrays and all other 
samples were compared to it. The arrays were normalized to spike-in standards which were 
present in equimolar rations in both Cy3- and Atto647-labeled aliquots. The array 
processing and quantification was performed with in-house python and R scripts. The data 
was submitted to the Gene Expression Omnibus (GEO) database and can be accessed using 
accession number GSE116812.
Chromatin immunoprecipitation.
ChIP was performed as previously described54. Chromatin fragments were prepared from 
DLD-1: MycER cells following 8hr of MYC activation (EtOH or 4-OHT treatment). DNA 
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was sonicated using Covaris 200 instrument at settings of Temp 5–9, PP200, DF 10, CB 200, 
720sec. 50μg DNA was used for each ChIP. The following antibodies were used to perform 
ChIP at a concentration of 5μg: ATF4 (cat# sc-200x, lot# G0115, c-20), MYC (cat# sc-764, 
lo#D0413, N-262). Rabbit IgG (cat# sc-2027x, lot# G2516) was used as a negative control. 
All antibodies were purchased from Santa Cruz Biotechnology. Protein G Dynabeads 
(10003D) were purchased from Invitrogen. Primers used for qPCR are listed in 
Supplementary Table 1.
Library preparation, sequencing and analysis.
ChIP DNA from two independent experiments was submitted to Wistar genomics core, 
(Wistar institute, Philadelphia) for library production using NEBNext Ultra II DNA Library 
Prep Kit for Illumina #E7645S and NEBNext Multiplex Oligos for Illumina #E7335S 
according to manufacturer’s instructions. The library fragments were assessed on an Agilent 
Technologies 2100 Bioanalyzer and yielded 150–350bp products. Illumina NextSeq 500 
instrument was used for sequencing. Select targets were validated by qPCR and primers 
used for qPCR are listed.
CHIP-seq data was aligned using bowtie55 against hg38 version of the human genome and 
HOMER software56 was used call significant peaks against IgG control or between 
corresponding replicate pairs of samples using–style factor option and only uniquely aligned 
reads with duplicates removed. Significant peaks that passed FDR<5% threshold and at least 
4 fold over IgG control were used to identify unique binding sites. Only results significant in 
comparison for both replicates were considered. De-novo motif analysis was performed 
using HOMER software among the list of sites with significant ATF4 binding in at least one 
condition (both replicates). Overlap of binding sites with genes was done using Ensemble 84 
transcriptome database. Genes with a binding site within 5kb from TSS were considered. 
Significance of overlap was tested using hypergeometric test using 23,869 Ensemble genes 
with Entrez ID as a population size. Gene set enrichment analysis of gene sets was done 
using QIAGEN’s Ingenuity® Pathway Analysis software (IPA®, QIAGEN Redwood 
City,www.qiagen.com/ingenuity) using “Canonical Pathways” and “Upstream Analysis” 
options. Pathways with at least 2 member genes that passed FDR<20%, enrichment at least 
5 fold threshold and upstream regulators (transcription factors only) that passed p<0.05 and 
had at least 5 target genes were considered. Functional and pathway enrichment analysis was 
done use DAVID software57 and FDR<20% categories enriched at least 5 fold were 
considered. The data was submitted to the Gene Expression Omnibus (GEO) database and 
can be accessed using accession number: GSE117240
Animal Studies.
All animal experiments were approved by Institutional Animal Care and Use Committee at 
University of Pennsylvania and comply with all regulations for ethical conduct of research. 
The Eμ-myc/+ (stock no. 002728), GCN2−/− (stock no. 008240) and Rosa26-CreERT2/+ 
(stock no. 008463) transgenic mice were purchased from The Jackson Laboratory. Athymic 
nude mice were purchased from Charles River Laboratory (stock no. 490). ATF4fl/fl mice 
under C57BL/6 background were generated by Cyagen Biosciences Inc. Briefly, LoxP sites 
were inserted flanking exon 2 and 3 of Atf4 locus to create a conditional knockout when 
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crossed with Rosa26-CreERT2/+. Eμ-myc/+; GCN2+/+ mice were crossed with GCN2−/− to 
generate Eμ-myc/+; GCN2+/+, Eμ-myc/+; GCN2+/− and Eμ-myc/+; GCN2−/− mice. ATF4fl/fl 
mice were crossed with Rosa26-CreERT2/+ to generate ATF4fl/fl; Rosa26-CreERT2/+ which 
were then crossed with Eμ-myc/+, ATF4 +/+ mice. The following mice were obtained and 
used for transplantable lymphoma experiments- Eμ-myc/+; Rosa26-CreERT2/+; ATF4wt/wt 
and Eμ-myc/+; Rosa26-CreERT2/+; ATF4fl/fl. Primers used for genotyping are listed in 
Supplementary Table 1.
For transplantable lymphoma experiments, mice harboring lymphoma were euthanized 
according to IACUC guidelines. Lymph nodes were collected immediately on ice and 
minced and passed through 70μm cell strainer in 50% Isclove’s media and 50% DMEM 
supplemented with 10% FBS, 1% Penicillin-Streptomycin and 4mM glutamine. Dead cells 
were removed by spinning cells in Ficoll-Paque PLUS (GE healthcare, # 17-1440-02), 800g 
for 10min. Lymphoma cells were washed in PBS and 2 million cells were injected into 9 
weeks old male C57BL/6J mice. Mice were monitored for lymphoma development by 
palpation every other day.
For PERK inhibitor (LY-4) experiments, 9 weeks old male mice were injected with 2 
milliion Eμ-myc/+; GCN2+/+ or Eμ-myc/+; GCN2−/− lymphoma cells. After 3 days mice 
were randomized to receive vehicle (Captisol, CYDEX) or LY-4 100mg/kg twice a day by 
oral gavage three days following lymphoma injection for the duration of the experiment. 
Moribund mice were euthanized as per IACUC guidelines and lymph nodes and spleen were 
harvested and assessed for protein levels by immunoblot.
For ATF4 excision experiment, 2 million Eμ-myc/+; Rosa26-CreERT2/+; ATF4wt/wt or Eμ-
myc/+; Rosa26-CreERT2/+; ATF4fl/fl lymphoma cells were injected via tail vein into 9-
weeks old male C57BL/6J mice. Three days following lymphoma injection, mice were 
randomized to receive vehicle (peanut oil, Sigma) or 4mg/20g Tamoxifen (T5648, Sigma) by 
oral gavage for 5 consecutive days. Mice were monitored every other day for lymphoma 
development by palpation.
3 million DLD-1, MycER, ishATF4 cells were injected in the flanks of 11-weeks old male 
nude mice and MYC was activated by treating mice with 1mg/mouse tamoxifen 3 days 
following tumor injection. Once tumors reached 100 cm3, 2mg/mouse doxycycline treatment 
was started for every other day until duration of experiment. Tumor volume was measured 
every 2–3 days and calculated as V = (L × W × H)/2, where L is tumor length, W is tumor 
width and H is height.
Statistics and Reproducibility.
All cell culture experiments were performed three times unless otherwise noted in the 
legend. GraphPad Prism 7 and Excel 2010 were used for statistical analysis. Error bars 
indicate mean ± S.D. or mean ± SEM (as indicated in Figure legends) and statistical 
significance was determined by unpaired, two tailed student’s t-test. One-way ANOVA 
analysis was used to determine statistical differences in the tRNA microarray data. A p value 
less than 0.05 was considered statistically significant. For mouse survival analysis, Kaplan-
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Meier curves and log-rank test were generated in GraphPad Prism 7 software. For xenograft 
experiment, two-way ANOVA was used.
Patient data analysis.
The gene expression using RNA-seq and survival information of DLBCL dataset58 were 
obtained from The NCI Center for Cancer Genomics (CCG) website, and gene expression 
information of 3 TCGA datasets was from UCSC Xena59 (Goldman et al. 2015). For each 
dataset, the normalized gene expression of EIF4EBP1 gene and other 10 ATF4 targeted 
genes (DDTI3, ATF3, ASNS, SLC43A1, SLC1A5, GARS, NARS, MARS, PSAT1, 
MTHFD2) was standardized to Z-score then the Pearson correlation between EIF4EBP1 and 
average ATF4 target genes was estimated. The visualization of linear relationships on Fig.6e 
was performed using seaborn software (https://zenodo.org/record/883859#.Ww2av0gvzAQ). 
In addition, patients in DLBCL dataset were divided into two groups according to ATF4/
EIF4EBP1 gene expression: low ATF4/EIF4EBP1 expression (</= median) and high ATF4/
EIF4EBP1 expression (> median). The survival analysis using Kaplan-Meier and log-rank 
test between high and low ATF4/EIF4EBP1 expression groups were performed using 
lifelines software (https://zenodo.org/record/1252342#.Ww2WRUgvzAQ), as shown on Fig. 
6f.
Data Availability
tRNA microarray and ChIP-seq data that support the findings of this study have been 
deposited in the Gene Expression Omnibus (GEO) under accession codes GSE116812 and 
GSE117240 respectively.
The human COAD, BRCA and SARC datasets were derived from the TCGA Data Hub on 
UCSC Xena platform (http://xena.ucsc.edu/).
The dataset derived from this resource that supports the findings of this study is available in 
links below:
COAD:
https://xenabrowser.net/datapages/?dataset=TCGA.COAD.sampleMap
%2FHiSeqV2_PANCAN&host=https%3A%2F%2Ftcga.xenahubs.net&removeHub=https
%3A%2F%2Flocal.xena.ucsc.edu%3A7223
BRCA:
https://xenabrowser.net/datapages/?dataset=TCGA.BRCA.sampleMap
%2FHiSeqV2_PANCAN&host=https%3A%2F%2Ftcga.xenahubs.net&removeHub=https
%3A%2F%2Flocal.xena.ucsc.edu%3A7223
SARC:
https://xenabrowser.net/datapages/?dataset=TCGA.SARC.sampleMap
%2FHiSeqV2_PANCAN&host=https%3A%2F%2Ftcga.xenahubs.net&removeHub=https
%3A%2F%2Flocal.xena.ucsc.edu%3A7223
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The human DLBCL data was derived from NCI Center for Cancer Genomics (CCG) 
website: https://gdc.cancer.gov. The data-set derived from this resource that supports the 
findings of this study is available in https://gdc.cancer.gov/about-data/publications/
DLBCL-2018.
Statistics Source Data giving rise to graphical representations and statistical analysis in 
Figures 1–6 and Supplemental Figures 1–6 have been provided as Supplementary Table 3. 
All other data supporting the findings of this study are available from the corresponding 
author on reasonable request.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. MYC induced ATF4 inhibits apoptosis and promotes survival.
a. Immunoblot of nuclear lysates from MEFs (left panel) and DLD-1 cells (right panel) 
expressing MycER were treated with 4-OHT to activate MYC. Thapsigargin (0.5μM for 4h) 
treated cells were used as a positive control for ATF4 induction. b. Immunoblot of nuclear 
lysates from P4936 (Tet-off MYC) cells treated with tetracycline (0.1ug/ml) or tetracycline 
was washed off for the indicated times. c. Immunoblot analysis of whole cell lysates from 
ATF4 +/+ and ATF4 −/− MEFs treated with 4-OHT for indicated times. d. Clonogenic 
survival was performed after activating MYC in MEFs, representative plates from three 
biological replicates are shown. Colonies were counted and surviving fraction is shown 
normalized to no treatment control. Error bars represent mean ± SD, two tailed student t-test. 
e. DLD-1: MycER cells were transfected with non-targeting siRNA or siRNA targeting 
ATF4. Cells were treated with 4-OHT and indicated proteins were assessed by 
immunoblotting. All immunoblots are representative of three biological replicates that 
showed similar results. Unprocessed scans of blots are shown in Supplementary Fig 7.
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Figure 2. The amino acid sensor GCN2 is activated by uncharged tRNAs and is required for 
optimal activation of ATF4 upon MYC induction.
a. Representative immunoblot showing activation of GCN2 following MYC induction using 
cytoplasmic lysates. b. DLD-1: MycER cells were transfected with non-targeting siRNA or 
siRNA against PERK, GCN2 or both. ISR signaling and apoptosis were assessed by 
immunoblotting after MYC activation. c. Representative immunoblot analysis of 
cytoplasmic and nuclear lysates from GCN2 +/+, GCN2−/− and ATF4−/− MycER MEFs 
after 16hrs of MYC activation. d. DLD-1: MycER cells were pretreated with DMSO or 
50μM RNA POLIII inhibitor (ML60218) for 2hrs prior to MYC activation. Indicated protein 
levels were measured by immunoblotting from cytoplasmic lysates. e. Microarray of 
aminoacyl–tRNAs of DLD-1: MycER cells after MYC induction at indicated times, four 
independent experiments, one-way ANOVA, *, p<0.05; **, p<0.01; ***, p< 0.001 (Refer to 
Statistics Source Data table for exact p values). (−) Leu denotes Leu-deprived cells and the 
marked tRNAs reading Leu codons are uncharged, n=1. tRNA probes are depicted with their 
cognate codon and the corresponding amino acid; Meti, initiator tRNAMet. Two different 
probes recognizing two different tRNALeu isodecoders that pair to the same codon TTA/G 
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Leu codon but differ in their sequence outside the anticodon were used on the arrays. 
Brackets show decreased charging of tRNALeu isodecoders in Leu deprivation condition. All 
immunoblots are representative of three biological replicates showing similar results. 
Unprocessed scans of blots are shown in Supplementary Fig 7.
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Figure 3. ATF4 and MYC bind to common target genes.
a. ATF4 ChIP-seq identified 330 binding sites for ATF4. Binding sites occupied by ATF4 
without 4-OHT and with 4-OHT are shown in blue and purple respectively. Binding sites 
that are significantly increased after 8 hours of MYC activation are shown in red. 
Significance of binding signal increase was estimated by HOMER algorithm (FDR<5%). b. 
Motif enriched within 330 ATF4 binding sites (human de-novo) and within ATF4 mouse 
experiment from GSE35681 dataset23. Table shows percent of binding sites containing the 
motif for different site groups. c. Transcription factors whose known targets were enriched 
among genes bound by ATF4, Z=z-score for predicted transcription activation state 
calculated by IPA based on number of targets shown to be activated by the TF. d. Overlap 
and its significance estimated by hypergeometric test of MYC and ATF4 bound genes in 8hr 
samples: sites co-bound by ATF4 and MYC within 5kb from genes’ TSS. e. List of all 33 
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genes from panel (d) that were bound by ATF4 and MYC at 8hrs of MYC activation. f. 
ChIP-seq signal track within TBC1D16 locus showing ATF4 and MYC binding peaks. 
ChIP-seq was performed twice in two independent experiments with similar results.
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Figure 4. ATF4 suppresses mTORC1 dependent signaling and inhibition of mTORC1 reduces 
cell death of ATF4 deficient cells following MYC activation.
a. ATF4 and MYC ChIP followed by qPCR at the EIF4EBP1 locus, n=3, technical 
replicates. Right schematic shows ATF4 and MYC peaks from ChIP-seq and locus for qPCR 
primers used. ChIP-seq was performed twice independently with similar results, 
neg=negative control. b. Representative Immunoblot of DLD-1, MycER cells assessing 
mTORC1 signaling in cells transfected with non- targeting siRNA or ATF4 siRNA. c. 
Representative immunoblot assessing ISR signaling in cells transfected with non-targeting 
siRNA or ATF4 siRNA. Tg, thapsigargin (0.5μM for 4hrs). d. Representative immunoblot of 
DLD-1 cells pretreated for 2 hours with 200nM Rapamycin followed by MYC activation. e. 
DLD-1: MycER cells were transfected with non-targeting siRNA or indicated siRNAs, and 
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proteins were assessed by immunoblotting after MYC activation. f. ATF4−/−, MycER MEFs 
were pretreated with Cyclohexamide (CHX) for indicated times followed by MYC 
activation. g. DLD-1: MycER cells were transfected with non-targeting siRNA or indicated 
siRNAs, and proteins were assessed by immunoblotting after MYC activation. All 
immunoblots are representative of three biological replicates that showed similar results. 
Unprocessed scans of blots are shown in Supplementary Fig 7.
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Figure 5. Acute ablation of ATF4 significantly delays MYC driven Lymphomagenesis and 
promotes survival of MYC driven lymphoma bearing mice.
a. Schematic showing allograft lymphoma model, where lymphoma cells are injected via tail 
vein into 9-weeks old C57BL/6J mice. Three days after lymphoma engraftment, mice are 
randomized to receive either vehicle or tamoxifen treatment by oral gavage for 5 days. b. 
Kaplan-Meier analysis for lymphoma-free survival of mice bearing Eμ-myc; ATF4fl/fl 
lymphoma treated with either vehicle (veh) or tamoxifen (tam) for 5 days. n=9 for Eμ-myc; 
ATF4fl/fl lymphoma tamoxifen group, all other groups n=10. Kaplan-Meier curves were 
analyzed by two-tailed log-rank test. c. Kaplan-Meier analysis for overall survival of mice 
bearing Eμ-myc; ATF4fl/fl lymphoma (left) or Eμ-myc; ATF4+/+ lymphoma (right). Kaplan-
Meier curves were analyzed by two-tailed log-rank test. d. Immunoblot of B cells isolated 
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from Eμ-myc; ATF4fl/fl lymphoma bearing mice a day after the last day of tamoxifen 
treatment. e. Lymph node weight of mice in panel d, n=3 per group, error bars represent 
mean ± SD, two tailed student t-test. f. Immunoblot of lymphoma lysates from mice in panel 
e. For d and f, lysates from three different mice per treatment were used. g. DLD-1, MycER, 
i-shATF4 cells were transplanted into 12-week-old nude mice and tumor size is shown. One 
(−) Dox mouse had to be sacrificed on day 12 because tumor reached maximum size limit. 
n=4 (−) Dox and n=4 (+) Dox. Two-way ANOVA, error bars represent mean± SEM. 
Unprocessed scans of blots are shown in Supplementary Fig 7.
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Figure 6. EIF4EBP1 positively correlates with ATF4 target gene expression and associates with 
poor prognosis.
a. Immunoblot of B cells isolated from WT (n=3), pre-lymphoma Eμ-myc (n=3) or 
lymphoma bearing Eμ-myc mice (n=6), lysates from different mice per group were used. b. 
Immunoblot from two normal human B cells (NHBC) and Burkitt’s lymphoma cell lines. c. 
Immunoblot from normal human colonocytes (NHC) or colon cancer cell lines. d. 
Immunoblot from MCF10 (non-tumorigenic breast epithelial cell line) or breast cancer cell 
lines. e. Pearson correlation between EIF4EBP1 and ATF4 target gene expression in 
Diffused Large B cell Lymphoma (DLBCL, n=562), Colorectal Adenocarcinoma (COAD, 
n=329), Breast Cancer (BRCA, n=1218) and Sarcoma (SARC, n=265). The center lines 
depict linear regression lines and shaded regions are 95% confidence intervals for regression 
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lines. Datasets analyzed are listed in the methods section. Previously known ATF4 target 
gene list used in this analysis is shown in table. f. Kaplan-Meier plots of progression free 
survival (left) and overall survival (right) of DLBCL patients with high or low EIF4EBP1 
expression. The survival analysis using Kaplan-Meier and two-sided log-rank test between 
high and low EIF4EBP1 expression groups was performed on all the patients with records of 
progression-free survival (left, n= 173) and overall survival (right, n=171), respectively. g. 
Proposed model of ATF4 and MYC co-operation in tumor progression. All immunoblots are 
from n=1 and unprocessed scans of blots are shown in Supplementary Fig 7.
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